FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:768-769 August 14, 2008 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

To the Editor: Alemtuzumab (Campath-1H) is a humanized anti-CD52 monoclonal antibody, the administration of which causes profound B- and T-lymphocyte depletion. It is licensed for use in the treatment of chronic lymphocytic leukemia, and it is increasingly used in the treatment of autoimmune diseases (particularly multiple sclerosis) and as an induction agent in renal transplantation. Although alemtuzumab is a potent immunosuppressant, several groups have described the paradoxical occurrence of autoimmune disease after its use, including thyroid disease and cytopenias. We describe two patients in whom anti–glomerular basement membrane disease developed after treatment with alemtuzumab.

Patient 1 was a 40-year-old white . . . [Full Text of this Article]

Related Letters:

More on Anti–Glomerular Basement Membrane Disease after Alemtuzumab
Shin J. I., Lee J. S., Clatworthy M. R., Wallin E. F., Jayne D. R.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:2501-2502, Dec 4, 2008. Correspondence

This article has been cited by other articles:

• Shin, J. I., Lee, J. S., Clatworthy, M. R., Wallin, E. F., Jayne, D. R. (2008). More on Anti-Glomerular Basement Membrane Disease after Alemtuzumab. NEJM 359: 2501-2502 [Full Text]